#1 Clinical Trials Search in Europe

Artemisia Vulgaris (312)

This article discusses clinical trials investigating the use of Artemisia Vulgaris (312), commonly known as mugwort, in allergy testing. These studies aim to assess the effectiveness and safety of sublingual immunotherapy for patients with various pollen allergies, including birch and grass pollen. While Artemisia Vulgaris is not the primary focus of these trials, it is used as a comparative allergen in skin prick tests to evaluate patients’ sensitivities.

Table of Contents

What is ARTEMISIA VULGARIS (312)?

ARTEMISIA VULGARIS (312), also known as 312 Mugwort, is an allergen extract used in diagnostic tests for allergic diseases[1]. It is derived from the mugwort plant, which is a common cause of allergies in some individuals. This substance is classified as a structurally diverse substance – allergen, meaning it contains various components that can trigger allergic reactions in sensitive people[1].

Medical Uses

The primary use of ARTEMISIA VULGARIS (312) is in diagnostic tests for allergic diseases, specifically in skin prick tests[1]. These tests are used to identify allergies in patients who may be experiencing symptoms such as:

  • Allergic rhinitis (hay fever)
  • Allergic conjunctivitis (eye allergy)
  • Asthma related to mugwort allergy
By using this allergen extract in a controlled medical setting, healthcare providers can determine if a patient is allergic to mugwort and develop appropriate treatment plans.

Administration

ARTEMISIA VULGARIS (312) is administered as a solution for skin-prick test[1]. The typical administration is as follows:

  • Route: Topical (applied to the skin)
  • Dose: Usually 1 drop
  • Frequency: Typically a one-time application during the allergy test
It’s important to note that this substance should only be administered by trained healthcare professionals in a controlled medical environment.

Clinical Trials

While the provided clinical trial information doesn’t directly involve ARTEMISIA VULGARIS (312) as the main study drug, it is mentioned as an auxiliary product in trials related to other allergens[1][2]. These trials focus on:

  • Assessing the efficacy and safety of sublingual immunotherapy for birch pollen allergy
  • Evaluating sublingual immunotherapy for grass pollen allergy
The inclusion of ARTEMISIA VULGARIS (312) in these trials suggests its importance in comprehensive allergy testing and diagnosis, even when studying other specific allergens.

Potential Side Effects

As ARTEMISIA VULGARIS (312) is used in diagnostic testing, the potential for side effects is generally low when used as directed. However, patients should be aware of the following possible reactions:

  • Local skin irritation at the test site
  • Itching or redness
  • In rare cases, a more severe allergic reaction
It’s crucial to inform your healthcare provider of any unusual reactions during or after the skin prick test.

Precautions

Before undergoing a skin prick test with ARTEMISIA VULGARIS (312), patients should:

  • Inform their doctor of all current medications, especially antihistamines or other allergy medications
  • Disclose any history of severe allergic reactions
  • Mention any skin conditions that might affect the test results
  • Follow all pre-test instructions provided by the healthcare team
Patients with a history of anaphylaxis or severe allergic reactions should be tested with extra caution and only under close medical supervision.

Aspect Details
Drug Name Artemisia Vulgaris (312)
Common Name Mugwort
Use in Trials Comparative allergen in skin prick tests
Product Form Solution for skin-prick test
Main Trial Objectives Assess efficacy and safety of sublingual immunotherapy for birch and grass pollen allergies
Target Conditions Moderate to severe allergic rhinitis/rhinoconjunctivitis due to specific pollens
Key Inclusion Criteria Adults 18-65, specific allergy history, positive skin prick test, elevated specific IgE levels
Primary Endpoint Differences in Combined Symptom and Medication Score (CSMS) during peak pollen periods

FAQ

  • What is Artemisia Vulgaris (312)? Artemisia Vulgaris (312), also known as mugwort, is a plant used in allergy testing. It's typically used in skin prick tests to help diagnose allergies by comparing a patient's reaction to various allergens.
  • How is Artemisia Vulgaris (312) used in these clinical trials? In these trials, Artemisia Vulgaris (312) is used as part of a skin prick test solution. It serves as a comparative allergen to help assess patients' sensitivities to other allergens like birch or grass pollen.
  • What is the main purpose of the clinical trials mentioned? The main purpose of these trials is to assess the efficacy and safety of sublingual immunotherapy for patients with birch or grass pollen allergies. They aim to determine the most effective and best-tolerated dose of the treatment.
  • What is sublingual immunotherapy? Sublingual immunotherapy is a type of allergy treatment where small amounts of an allergen are placed under the tongue to help the body build tolerance over time, potentially reducing allergic reactions.
  • Who can participate in these clinical trials? Participants are typically adults aged 18-65 with moderate to severe allergic rhinitis or rhinoconjunctivitis due to specific pollens (birch or grass) for at least two years. They must meet certain criteria, including positive skin prick tests and specific IgE levels to the relevant allergens.

Ongoing Clinical Trials on Artemisia Vulgaris (312)

  • Study on the Effectiveness and Safety of Phleum Pratense Pollen Extract for Patients with Moderate-to-Severe Grass Pollen Allergy

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness and Safety of Sublingual Immunotherapy with Betula Pendula Pollen Extract for Patients with Birch Pollen Allergy

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Allergic rhinitis: An allergic reaction affecting the nose, causing symptoms such as sneezing, runny nose, and nasal congestion in response to allergens like pollen.
  • Rhinoconjunctivitis: A combination of rhinitis (nasal symptoms) and conjunctivitis (eye symptoms) often caused by allergies.
  • Sublingual immunotherapy: A treatment for allergies where small amounts of an allergen are placed under the tongue to help the body build tolerance over time.
  • Skin prick test: A method used to diagnose allergies by placing a small amount of an allergen on the skin and pricking the surface to see if a reaction occurs.
  • IgE (Immunoglobulin E): An antibody produced by the immune system in response to allergens, often measured to diagnose allergies.
  • CSMS (Combined Symptom and Medication Score): A measure used in allergy studies to assess the severity of symptoms and the need for medication.
  • FEV1 (Forced Expiratory Volume in 1 second): A measure of lung function, specifically how much air a person can exhale in one second.
  • Nasal provocation test: A test where an allergen is applied to the nose to diagnose or assess the severity of nasal allergies.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-immunotherapy-with-betula-pendula-pollen-extract-for-patients-with-birch-pollen-allergy/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-phleum-pratense-pollen-extract-for-patients-with-moderate-to-severe-grass-pollen-allergy/